JP2011509094A5 - - Google Patents

Download PDF

Info

Publication number
JP2011509094A5
JP2011509094A5 JP2010542284A JP2010542284A JP2011509094A5 JP 2011509094 A5 JP2011509094 A5 JP 2011509094A5 JP 2010542284 A JP2010542284 A JP 2010542284A JP 2010542284 A JP2010542284 A JP 2010542284A JP 2011509094 A5 JP2011509094 A5 JP 2011509094A5
Authority
JP
Japan
Prior art keywords
cadherin
antagonist
antibody
seq
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010542284A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011509094A (ja
JP5511684B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/000162 external-priority patent/WO2009089062A2/en
Publication of JP2011509094A publication Critical patent/JP2011509094A/ja
Publication of JP2011509094A5 publication Critical patent/JP2011509094A5/ja
Application granted granted Critical
Publication of JP5511684B2 publication Critical patent/JP5511684B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010542284A 2008-01-11 2009-01-09 炎症性関節障害を治療するためのカドヘリン−11eclドメインアンタゴニスト Expired - Fee Related JP5511684B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1073408P 2008-01-11 2008-01-11
US61/010,734 2008-01-11
PCT/US2009/000162 WO2009089062A2 (en) 2008-01-11 2009-01-09 Cadherin-11 ecl domain antagonists for treating inflammatory joint disorders

Publications (3)

Publication Number Publication Date
JP2011509094A JP2011509094A (ja) 2011-03-24
JP2011509094A5 true JP2011509094A5 (enExample) 2012-02-23
JP5511684B2 JP5511684B2 (ja) 2014-06-04

Family

ID=40602259

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010542284A Expired - Fee Related JP5511684B2 (ja) 2008-01-11 2009-01-09 炎症性関節障害を治療するためのカドヘリン−11eclドメインアンタゴニスト

Country Status (15)

Country Link
US (4) US8591888B2 (enExample)
EP (2) EP2242769B1 (enExample)
JP (1) JP5511684B2 (enExample)
CN (1) CN101952316B (enExample)
AU (1) AU2009204467B2 (enExample)
BR (1) BRPI0906492A2 (enExample)
CA (1) CA2711394A1 (enExample)
DK (1) DK2242769T3 (enExample)
ES (1) ES2611102T3 (enExample)
HU (1) HUE031207T2 (enExample)
IL (1) IL206880A (enExample)
MX (1) MX2010007551A (enExample)
PL (1) PL2242769T3 (enExample)
SI (1) SI2242769T1 (enExample)
WO (1) WO2009089062A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE031207T2 (hu) * 2008-01-11 2017-07-28 Adheron Therapeutics Inc Cadherin-11 EC1 domén elleni antitestek gyulladásos ízületi rendellenességek kezeléséhez
EP3138915A1 (en) * 2010-05-04 2017-03-08 The Brigham and Women's Hospital, Inc. Detection and treatment of fibrosis
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
CA2805112A1 (en) * 2010-07-15 2012-01-19 Synovex Corporation Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
EP2819672A1 (en) 2012-02-29 2015-01-07 Pulmatrix, Inc. Inhalable dry powders
KR20130142025A (ko) * 2012-06-18 2013-12-27 한국생명공학연구원 카드헤린―11 단백질의 발현 또는 활성 억제제를 포함하는 대장암 치료 또는 전이 억제용 약학적 조성물
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
EP3302530B1 (en) * 2015-05-29 2022-05-25 Children's Hospital Medical Center Cdh26 based therapeutic agents and their use
KR101654526B1 (ko) * 2015-10-19 2016-09-06 한국생명공학연구원 카드헤린―11 단백질의 발현 또는 활성 억제제를 포함하는 대장암 치료 또는 전이 억제용 약학적 조성물
EP3402572B1 (en) 2016-01-13 2022-03-16 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
EP3781588B1 (en) 2018-04-20 2024-10-30 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US215482A (en) * 1879-05-20 Improvement in spring be d-bottoms
US229199A (en) * 1880-06-22 Wood-working machine
US248220A (en) * 1881-10-11 Machine for graining and dicing leather
US8323A (en) * 1851-08-26 colne
US110755A (en) * 1871-01-03 Improvement in spike-machines
US96746A (en) * 1869-11-09 Improvement in mechanical movements
US229811A (en) * 1880-07-13 dtjnlop
US248219A (en) * 1881-10-11 Panorama-toy
US253200A (en) * 1882-02-07 Timothy guilford
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0232262A4 (en) 1985-08-15 1989-09-19 Stauffer Chemical Co TRYPTOPHANE GENERATING MICROORGANISM.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
EP1695978A1 (en) 1990-06-11 2006-08-30 Gilead Sciences, Inc. Nucleic acid ligands
DE10075010I2 (de) 1990-06-28 2004-01-29 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
US5859136A (en) * 1997-11-03 1999-01-12 E. I. Du Pont De Nemours And Company Coating composition containing an amine functional dispersed polymer and an isocyanate curing agent
EP1075494A2 (en) * 1998-05-05 2001-02-14 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US7481999B2 (en) * 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
US6472367B1 (en) * 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
US6638911B1 (en) * 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
US6787136B1 (en) * 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
PT1207905E (pt) * 1999-09-03 2010-12-07 Brigham & Womens Hospital Métodos e composições para o tratamento de doença inflamatória utilizando agentes moduladores da caderina-11
US20040110755A1 (en) * 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
WO2004048411A2 (en) * 2002-11-14 2004-06-10 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
US6952969B2 (en) * 2003-09-30 2005-10-11 The Aerospace Corporation Ceramic ball bearing fracture test method
WO2006089397A1 (en) * 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Methods for treating arthritis using triheterocyclic compounds
HUE031207T2 (hu) * 2008-01-11 2017-07-28 Adheron Therapeutics Inc Cadherin-11 EC1 domén elleni antitestek gyulladásos ízületi rendellenességek kezeléséhez
CN101998966A (zh) 2008-02-11 2011-03-30 诺瓦提斯公司 使用钙黏着蛋白11(cdh11)拮抗剂的方法
AU2010242338B2 (en) * 2009-05-01 2013-12-19 Perseus Proteomics Inc. Anti-cadherin antibody
CA2805112A1 (en) 2010-07-15 2012-01-19 Synovex Corporation Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods

Similar Documents

Publication Publication Date Title
JP2011509094A5 (enExample)
US10072076B2 (en) Human antibodies to NAv1.7
JP6152433B2 (ja) 抗tnf−抗il−17二重特異性抗体
US20250101123A1 (en) Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
SI2593128T1 (en) Humanized antibodies targeting the EC1 Kaderina-11 domain and associated compositions and procedures
JP2019505564A (ja) 抗bcmaポリペプチド及びタンパク質
JP2018503401A (ja) 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用
US11667704B2 (en) Anti-IL-17 antibody/TNFR ECD fusion protein and use thereof
CA3173414A1 (en) Pd-1 agonist multimeric binding molecules
CN110267977A (zh) 细胞因子免疫球蛋白Fc融合异二聚体和包含其的药物组合物
JP2016520619A5 (enExample)
JP2012514997A (ja) 組換え一価抗体
CN112469735B (zh) 用于治疗自发性疾病和癌症的抗cxcl13抗体
JP7386877B2 (ja) 新規の抗ifnar1抗体
CN118240082A (zh) Pd-1结合分子及其应用
CN103897057B (zh) 多价抗体片段与其三聚复合物
ES2983249T3 (es) Anticuerpo humano frente a especies de ADAMTS de tipo agrecanasa para agentes terapéuticos de enfermedades relacionadas con agrecanasa
WO2015113494A1 (zh) 双功能融合蛋白及其制备方法和用途
CN111886024A (zh) 抗tip-1抗体及其用途
US9580502B2 (en) Compositions for selective reduction of circulating bioactive soluble TNF and methods for treating TNF-mediated disease
US20240141026A1 (en) Use of a periostin antibody for treating inflammation, fibrosis and lung diseases
US20250340632A1 (en) SPECIFIC ANTAGONIST ANTI-SIRPg ANTIBODIES
US20160215047A1 (en) Bispecific antibody against tnf-alpha and synovial microvasculature of arthritis patients
CN121181689A (zh) 用于减少融合蛋白错配的蛋白及其应用
CN118725136A (zh) 抗pd-1/抗tigit双特异性抗体与il-2的融合蛋白及应用